These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15878389)

  • 1. A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination.
    Rascati KL; Stanford RH; Borker R
    Clin Ther; 2005 Mar; 27(3):346-54. PubMed ID: 15878389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
    Delea TE; Hagiwara M; Dalal AA; Stanford RH; Blanchette CM
    Curr Med Res Opin; 2009 Jan; 25(1):1-13. PubMed ID: 19210134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
    Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE
    J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary disease.
    Anzueto A; McLaughlin T; Stanford RH
    COPD; 2004; 1(2):205-14. PubMed ID: 17136988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
    Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
    Cramer JA; Bradley-Kennedy C; Scalera A
    Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA; Shah M; D'Souza AO; Crater GD
    Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
    Stempel DA; O'Donnell JC; Meyer JW
    J Allergy Clin Immunol; 2002 Mar; 109(3):433-9. PubMed ID: 11897987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.